John C. Reed, an insider at Johnson & Johnson (JNJ), has purchased 43,442 shares of the company at a price of $157.92 per share, amounting to a total transaction value of $6.86 million. This acquisition occurred on October 16, 2025, bringing Reed's total holdings in the company to 43,442 shares.
Johnson & Johnson operates in the pharmaceuticals sector, focusing on research, development, and manufacturing of healthcare products. The company, headquartered in New Brunswick, New Jersey, employs approximately 138,100 full-time staff. With a market capitalization of $486.4 billion, Johnson & Johnson has a P/E ratio of 19.37 and an EPS of 10.36. The company is also known for its diverse product offerings in its Innovative Medicine and MedTech segments, which include treatments for various therapeutic areas such as oncology and cardiovascular health.
This recent insider buying activity may be seen as a sign of confidence in the company’s future prospects, as executives often possess insights into the company’s operations. However, it is important for investors to consider such transactions in conjunction with broader trends in insider trading rather than as standalone indicators.
Investors should pay attention to the upcoming earnings report scheduled for April 13, 2026, where the company is expected to announce an EPS of $2.79 and revenue of $23.2 billion, and again on July 14, 2026, with an EPS estimate of $2.93 and revenue of $25.1 billion. These figures will provide further context for evaluating the company’s performance and future outlook.